A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America

Table 6 Summary of hereditary cancer registries data from tumor MMR analysis from suspected Latin America LS families

Latin American Institutions	Number of families	Number of individuals	Age at CRC diagnosis (mean ± SD)	Age at endometrial cancer diagnosis (mean ± SD)	Clinical criteria		MMR deficient (%)	MMR non-deficient (%)
Latin American Institutions	Number of families	Number of individuals	Age at CRC diagnosis (mean ± SD)	Age at endometrial cancer diagnosis (mean ± SD)	AMSII	Revised Bethesda	MMR deficient (%)	MMR non-deficient (%)
Instituto Nacional de Enfermedades Neoplásicas (Lima, Peru)^a	82	83	41(13.1)	52(9.01)	22	60	40(48.2)	43(51.8)
Centro de EnfermedadesNeoplasicas Oncovida (La Paz, Boliva)^b	46	61	27.7(12.7)	na	46	0	3(4.9)	58(95.1)
Instituto Nacional de Cancerología de México (Mexico City, Mexico)^c	23	60	33(14.6)	37.5(12.02)	11	12	23(38.3)	37(61.7)
Hospital Privado Universitario de Cordoba (Cordoba, Argentina)^c	6	6	43.3(8.7)	NA	0	6	3(50.0)	3(50.0)
Total	157	210			79	78	69(32.8)	141(67.2)

a: MMR deficiency analyzed based on IHC and/or MSI; b: MMR deficiency based on BAT-25 MSI marker; c: MMR deficiency based on IHC; NA: not applied; MMR: mismatch-repair; CRC: colorectal cancer; SD: standard deviation; IHC: immunohistochemistry; MSI: microsatellite instability; MSI-H: MSI-high; MSS: microsatellite stable

ISSN: 1471-2407